Mami Tomita

Mami Tomita

Auto-generated profile, based on publicly available information

Mami Tomita


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 August 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MTMami Tomita
Mami Tomita
Manabu YamamotoManabu Yamamoto
Manabu Yamamoto
KHKumiko Hirayama
Kumiko Hirayama
AKAkika Kyo
Akika Kyo
NMNorihiko Misawa
Norihiko Misawa
Shigeru HondaShigeru Honda
Shigeru Honda
Objectives: To evaluate the one-year outcomes of intravitreal ranibizumab biosimilar (RBZ-BS) injections for myopic choroidal neovascularization (mCNV) in Japanese patients. Methods: Twenty-one patients (mean age 69.0 years; 4 males, 17 females) with high myopia and mCNV were retrospectively reviewed. Twelve were treatment-naïve, and nine had previous anti-VEGF treatments. Efficacy measures included best-corrected visual acuity (BCVA) and central macular thickness (CMT). Results: The treatment-naïve group showed significant BCVA improvement from 0.55 ± 0.34 at baseline to 0.24 ± 0.28 at 12 months. The previously treated group had no significant BCVA changes. CMT significantly decreased in both groups: from 295.3 ± 105.2 µm to 207.3 ± 63.0 µm in the treatment-naïve group, and from 196.1 ± 62.0 µm to 147.2 ± 50.1 µm in the previously treated group. Dry macula rates were high: 83% at 3 months and 83% at 12 months in the treatment-naïve group, and 67% at 3 months and 89% at 12 months in the previously treated group. No adverse events were reported. Conclusions: These findings indicate that RBZ-BS is an effective and safe treatment for mCNV, particularly in treatment-naïve patients. The use of RBZ-BS offers a cost-effective alternative to original ranibizumab, reducing financial burdens while maintaining high therapeutic efficacy. Further studies with larger sample sizes and longer follow-up periods are needed to confirm these results and evaluate long-term outcomes and cost-effectiveness.

23 February 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
YHYusuke Haruna
Yusuke Haruna
MTMizuki Tagami
Mizuki Tagami
MTMami Tomita
Mami Tomita
ASAtsushi Sakai
Atsushi Sakai
NMNorihiko Misawa
Norihiko Misawa
Shigeru HondaShigeru Honda
Shigeru Honda
Objectives: We investigate the correlation between functional and morphological changes in extraocular muscles (EOMs) and intraocular pressure (IOP) changes before and after thyroid eye disease (TED) treatment. Methods: A multicenter study with a retrospective chart review was conducted. Patients with active TED receiving corticosteroid therapy without glaucoma eye drops between 2014 and 2023 were reviewed. Various parameters were measured by magnetic resonance imaging. The primary outcome measure was the correlation between changes in the IOP and the cross-sectional area (CSA) of the EOMs before and after treatment. Secondary outcome measures were comparisons of IOP, the signal intensity ratio (SIR) of the EOMs and orbital fatty tissue (OFT), and the CSA of the EOMs before and after treatment. Results: The IOP in 99 eyes in 51 patients significantly decreased from 18 ± 3.4 mmHg to 15.5 ± 2.9 mmHg before and after treatment (p < 0.01)). The CSA and SIR of all EOMs and OFT significantly decreased after treatment (p < 0.05). Factors that had a significant positive correlation with the IOP change rate before and after treatment were the CSA change rate of the inferior rectus muscle (IRM) before and after treatment (Spearman’s correlation coefficient, R2 = 0.24, p < 0.05) and the CSA change rate of the total EOMs before and after treatment (Spearman’s correlation coefficient, R2 = 0.22, p < 0.05). Conclusions: In TED patients, IOP decreased with anti-inflammatory treatment alone. The most significant parameter that correlated with the decrease in IOP was the CSA change rate of the IRM.

29 April 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
YUYosuke Ueno
Yosuke Ueno
YHYusuke Haruna
Yusuke Haruna
MTMami Tomita
Mami Tomita
ASAtsushi Sakai
Atsushi Sakai
SOShogo Ogawa
Shogo Ogawa
Shigeru HondaShigeru Honda
Shigeru Honda
Purpose: To examine the effectiveness of patterned laser trabeculoplasty (PSLT) as an additional treatment for patients of open-angle glaucoma (OAG) receiving maximized ocular hypotensive medications (OHM). Methods: Forty eyes of 33 patients (average age 72.7±10.7 years) who had not previously undergone open glaucoma surgery or laser trabeculoplasty and were treated with maximized OHM between June 2018 and March 2022 were included. A 360-degree PSLT was conducted and postoperative intraocular pressure (IOP) and survival curves at 1, 3, 6, 9, and 12 months were evaluated. Results: According to the Kaplan-Meier survival analysis, the average survival time was 8.1 months with death defined as postoperative IOP reduction of less than 10% or requiring additional treatment. The average survival time was 4.9 months with death defined as postoperative IOP reduction of less than 20% or requiring additional treatment. In the 31 eyes which received no additional treatment after PSLT, the mean preoperative IOP was 18.5±3.9 mmHg, which reduced to 15.3±4.1 mmHg (p=1.62 x 10-6)), 15.5±3.4 mmHg (p=1.51 x 10-5), 15.7±4.0 mmHg (p=1.75 x 10-5), 14.7±4.38 (p=2.89 x 10-6), and 15.0±4.0 mmHg (p=5.74 x 10-9) at 1, 3, 6, 9 and 12 months after PSLT, respectively. The IOP reduction rate one year after PSLT was 18.7%. Thirteen of the 31 eyes (42%) achieved a 20% reduction in IOP compared to the baseline. Conclusion: Adjunctive treatment with PSLT in OAG patients receiving maximized OHM may be effective over 12-months of follow-up.